Beam Therapeutics Stock Today
| BEAM Stock | USD 27.20 1.36 5.26% |
Performance2 of 100
| Odds Of DistressLess than 12
|
Beam Therapeutics is selling at 27.20 as of the 28th of November 2024; that is 5.26 percent increase since the beginning of the trading day. The stock's lowest day price was 26.09. Beam Therapeutics has less than a 12 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Beam Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of February 2020 | Category Healthcare | Classification Health Care |
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 82.81 M outstanding shares of which 11.97 M shares are currently shorted by private and institutional investors with about 9.35 trading days to cover. More on Beam Therapeutics
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Beam Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBeam Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Beam Therapeutics' financial leverage. It provides some insight into what part of Beam Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beam Therapeutics (BEAM) is traded on NASDAQ Exchange in USA. It is located in 238 Main Street, Cambridge, MA, United States, 02142-1016 and employs 472 people. Beam Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.25 B. Beam Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 82.81 M outstanding shares of which 11.97 M shares are currently shorted by private and institutional investors with about 9.35 trading days to cover.
Beam Therapeutics currently holds about 1.09 B in cash with (149.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9.
Check Beam Therapeutics Probability Of Bankruptcy
Ownership AllocationBeam Therapeutics holds a total of 82.81 Million outstanding shares. The majority of Beam Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Beam Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Beam Therapeutics. Please pay attention to any change in the institutional holdings of Beam Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Beam Ownership Details
Beam Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 1.8 M | |
| Redmile Group, Llc | 2024-09-30 | 1.6 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.6 M | |
| Bellevue Group Ag | 2024-09-30 | 1.5 M | |
| Citadel Advisors Llc | 2024-09-30 | 1.5 M | |
| First Trust Advisors L.p. | 2024-06-30 | 1.5 M | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 1.4 M | |
| Kynam Capital Management, Lp | 2024-09-30 | 1.3 M | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.2 M | |
| Farallon Capital Management, L.l.c. | 2024-09-30 | 8.2 M | |
| Vanguard Group Inc | 2024-09-30 | 7.8 M |
Beam Therapeutics Historical Income Statement
Beam Stock Against Markets
Beam Therapeutics Corporate Management
| Manmohan Singh | Chief Officer | Profile | |
| Nicole Gaudelli | CoFounder | Profile | |
| Brian Riley | VP Operations | Profile | |
| Susan OConnor | Chief Officer | Profile | |
| Alexis Komor | CoFounder | Profile | |
| Amy MD | Chief Officer | Profile | |
| Suzanne Fleming | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share 4.273 | Quarterly Revenue Growth (0.17) | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.